XRCC4 and ovarian carcinoma: Our study reveals that the XRCC4 in the NHEJ pathway contributes to platinum resistance by reducing DNA damage and provides preclinical evidence for targeting XRCC4 as a new strategy to overcome cisplatin resistance in ovarian cancer treatment.